3-(4,6-dimethyl-3-phenyl-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methylquinazolin-4(3H)-one | 1394357-31-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-(4,6-dimethyl-3-phenyl-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methylquinazolin-4(3H)-one
• 英文别名: 3-(4,6-dimethyl-3-phenyl-2-sulfanylidene-4H-pyrimidin-1-yl)-2-methylquinazolin-4-one
• CAS: 1394357-31-3
• 化学式: C₂₁H₂₀N₄OS
• 分子量: 376.482
• InChiKey: GMNYUWYBLMHNDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  27
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  71.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-氨基-2-甲基-4(3H)喹唑啉酮 在 哌啶 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 27.0h， 生成 3-(4,6-dimethyl-3-phenyl-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methylquinazolin-4(3H)-one
  参考文献：
  名称：

  Antitumor and antileishmanial evaluation of novel heterocycles derived from quinazoline scaffold: a molecular modeling approach

  摘要：

  Novel thiazole, pyrimidine and benzylidene derivatives derived from quinazoline scaffold have been synthesized. The antitumor evaluation of the newly synthesized products against three cancer cell lines namely breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460), and CNS cancer (SF-268) showed that the benzylidene-quinazoline derivative 12a showed remarkable activity against all three cell lines. The thiazolo-quinazoline derivative 10 showed greater activity than the control against breast adenocarcinoma (MCF-7) with a concentration of 0.01 mu M. Moreover, the antileishmanial activity of the newly synthesized products tested on Leishmania donovani amastigotes showed that compounds 4, 14, and 18 had very promising activity.

  DOI：

  10.1007/s00044-012-0213-9

文献信息

• Antitumor and antileishmanial evaluation of novel heterocycles derived from quinazoline scaffold: a molecular modeling approach
  作者：Daisy H. Fleita、Rafat M. Mohareb、Ola K. Sakka

  DOI：10.1007/s00044-012-0213-9

  日期：2013.5

  Novel thiazole, pyrimidine and benzylidene derivatives derived from quinazoline scaffold have been synthesized. The antitumor evaluation of the newly synthesized products against three cancer cell lines namely breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460), and CNS cancer (SF-268) showed that the benzylidene-quinazoline derivative 12a showed remarkable activity against all three cell lines. The thiazolo-quinazoline derivative 10 showed greater activity than the control against breast adenocarcinoma (MCF-7) with a concentration of 0.01 mu M. Moreover, the antileishmanial activity of the newly synthesized products tested on Leishmania donovani amastigotes showed that compounds 4, 14, and 18 had very promising activity.